+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
39 locations
E

Actively Recruiting

Researchers are studying treatments for advanced solid tumors, which are cancers that have spread and often become resistant to existing therapies. This trial evaluates the safety, tolerability, how the body processes Mocertatug Rezetecan Mo-Rez, and its effectiveness when combined with other cancer medicines. Participants include adults with advanced solid tumors who have not responded to standard treatments, cannot tolerate them, or lack effective options. Participants will receive Mo-Rez intravenously, combined either with Dostarlimab for endometrial cancer or with Bevacizumab for ovarian cancer. The study is randomized, with multiple treatment groups, and includes two parts Part A focusing on dose-limiting toxicities and safety over about 7 to 22 months, and Part B assessing confirmed tumor response and survival outcomes up to approximately 37 months. During the trial, participants undergo regular evaluations including tumor assessments by RECIST criteria, biomarker analyses from tumor tissue samples, vital sign monitoring, lab tests, and ECGs. Researchers track adverse events, immune responses, drug concentrations, and quality of life measures. The study lasts up to nearly three years with ongoing safety and efficacy monitoring throughout.

Age: 18Years +All GendersPhase 1Phase 2
83 locations